BRAF and metastatic melanoma: Monotherapy with BRAF inhibitors and combined therapy with BRAF inhibitors and MEK inhibitors have been approved by the Food and Drug Administration in the United States of America and other countries worldwide for targeted therapy of metastatic melanoma [5–10].